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Abstract
Background: Sleep disruption is one of the most commonly reported quality of life concerns
among cancer patients who have undergone hematopoietic stem cell transplantation (HSCT).
Despite the high percentage of patients reporting sleep concerns, relatively little research has
characterized sleep problems or explored relationships with psychological factors. In addition, no
studies have used actigraph technology to characterize sleep issues among transplant recipients.
Method: Autologous HSCT recipients who were 6 to 18 months post-transplant were invited to
participate. Patients completed self-report measures of cancer-related distress, fear of cancer
recurrence, dysfunctional cognitions about sleep, and maladaptive sleep behaviors upon
enrollment, wore an actigraph and completed a sleep log at home for 7 days, and completed a
self-report measure of sleep disruption on day 7 of the study.
Results: 84 autologous HSCT recipients (age M = 60, 45% female) were enrolled and provided
complete data. Forty-one percent of patients met criteria for sub-clinical or clinical insomnia
based on patient self-report. Examination of actigraph data indicated that certain aspects of sleep
were poorer than others (wake after sleep onset M = 66 minutes; total sleep time M = 6.5 hours;
sleep efficiency M = 78%; sleep onset latency M = 21 minutes). Measures of cancer-related
distress, fear of cancer recurrence, cognitive distortions, and maladaptive behavioral patterns
were related to subjectively reported sleep disruption, p’s < .05, but were not related to
objectively measured sleep disruption. Further examination revealed that the cognitive and
behavioral factors accounted for the largest unique variance in subjectively reported sleep
disruption.
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Conclusion: Results from the present study suggest that many HSCT recipients continue to
experience sleep disruption during the survivorship period following transplant. Cancer-specific
factors, dysfunctional cognitions about sleep, and maladaptive sleep behaviors were related to
self-reported sleep disruption and are ripe targets for a cognitive behavioral intervention.
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Introduction
Hematopoietic stem cell transplantation (HSCT) is an intensive therapy used to treat
hematologic malignancies including leukemia, lymphoma, and multiple myeloma. Cancer
patients undergoing this difficult procedure are at risk for a host of treatment-related
complications and mortality (Copelan, 2006). In addition to acute treatment-related side effects,
many patients continue to experience decrements in quality of life during the post-treatment
period. Some of the most common quality of life concerns reported by patients following HSCT
include fatigue, lack of appetite, nausea, pain, and sleep disruption (Cohen et al., 2012; Anderson
et al., 2007). Sleep disruption may include problems falling asleep or staying asleep, waking
earlier than planned, and/or experiencing non-restorative sleep (American Psychiatric
Association, 2000). Although sleep disruption has been linked with greater distress, fatigue,
depressive symptoms, and worse quality of life among cancer patients recovering from transplant
(Rischer, Scherwath, Zander, Koch, & Schulz-Kindermann, 2009; Bevans, Mitchell, & Marden,
2008; Andrykowski et al., 1997), it has often been overlooked or minimized. With these
considerations in mind, the current study aimed to determine the prevalence of sleep disruption
following HSCT and sought to identify cancer-specific and cognitive-behavioral factors that
contribute to this sleep disruption.
Prevalence of Sleep Disruption Among HSCT Recipients
Sleep disruption is one of the most common quality of life concerns following HSCT
(Cohen et al., 2012; Bevans et al., 2008) with as many as 77% of patients reporting sleep
difficulties (Rischer et al., 2009). In a report by Faulhaber and colleagues, insomnia was the most
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prevalent sleep disorder with 23% of HSCT recipients between 1 and 10 years post-transplant
reporting problems with insomnia (Faulhaber et al., 2010). Another report by Boonstra and
colleagues indicates that 48% of hospitalized HSCT recipients experience subthreshold insomnia
symptoms, 23% experience moderate levels of insomnia, and 3% experience severe levels of
insomnia (Boonstra et al., 2011). Moreover, it has been consistently demonstrated that sleep
quality is worse among HSCT recipients than healthy individuals (Pallua et al., 2010; Bieri et al.,
2008; Bishop et al., 2007; Syrjala, Langer, Abrams, Storer, & Martin, 2005; Andrykowski et al.,
2005; Gulbrandsen, Hjermstad, & Wisloff, 2004; Edman, Larsen, Hagglund, & Gardulf, 2001;
Prieto et al., 1996). It should be noted, however, that much of what is known about sleep
disruption among HSCT recipients has been gathered from studies that focus more broadly on
quality of life following transplant. Consistent with this broader emphasis, many of these studies
have utilized only single-item measures of perceived sleep quality. Additional methodological
limitations that characterize much of this research include small sample sizes and exclusive
reliance upon self-report with no use of currently available actigraph technology.
Actigraphy involves the objective measurement of movement by means of an
accelerometer that records and averages wrist movements (Ancoli-Israel et al., 2003). It has been
successfully used to measure sleep/wake patterns in breast and gynecologic cancer patients (Liu
et al., 2013; Ancoli-Israel et al., 2006; Jim et al., 2011) as well as patients with advanced cancer
(Ma, Chang, & Lin, 2014). For example, studies of breast cancer patients have shown that
chemotherapy administration is likely to result in shortened time asleep at night (approximately 6
hours), longer time awake at night (approximately 2 hours), and frequent and longer napping
during the day (approximately 1 hour) (Liu et al., 2012; Ancoli-Israel et al., 2006; Berger, Farr,
Kuhn, Fischer, & Agrawal, 2007). Moreover, prior research indicates that objective
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measurements of sleep using actigraphy do not always align with self-reports of perceived sleep
quality (Lauderdale, Knutson, Yan, Liu, & Rathouz, 2008; Miaskowski & Lee, 1999).
Surprisingly, a review of the literature did not identify any published studies that have used
actigraphy to measure sleep following HSCT. To address this gap in knowledge, the present
study used both a self-report measure (the Insomnia Severity Index [ISI]) and actigraphy to
measure sleep disruption following HSCT.
Trajectory of Sleep Disruption Following HSCT
The focus of many reports examining sleep among HSCT recipients has been on
investigating the trajectory of sleep quality in the immediate recovery period following the
transplant as well as during the post-treatment survivorship period. Research on the trajectory of
sleep problems indicates that sleep quality declines from the period prior to transplant through
hospital discharge and eventually returns to pre-transplant levels between hospital discharge and
day 100 post-transplant (Rischer et al., 2009; Anderson et al., 2007; Hacker & Ferrans, 2003).
Although sleep quality tends to return to pre-transplant levels relatively quickly, sleep is
considerably compromised even prior to transplant with a majority of HSCT recipients endorsing
sleep difficulties before transplantation (Bevans et al., 2008). Moreover, sleep quality appears to
remain relatively stable and does not further improve following day 100 post-transplant
suggesting that sleep difficulties are not only highly prevalent, but also are a persistent problem
among HSCT survivors (Frodin, Borjeson, Lyth, & Lotfi, 2011; Worel et al., 2002; Bush,
Donaldson, Haberman, Dacanay, & Sullivan, 2000; Andrykowski et al., 1999; Kopp et al., 1998;
Andrykowski et al., 1997; Andrykowski, Bruehl, Brady, & Henslee-Downey, 1995). Therefore,
an argument could be made that examining sleep disruption between 6 and 18 months post-
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transplantation would provide a snapshot of these concerns during a time in which they tend to
be relatively stable.
Predictors and Correlates of Sleep Disruption
Prior studies examining risk factors for sleep disruption have generally focused on
demographic and clinical predictors, factors that are typically not amenable to intervention. For
example, older age (Watson et al., 2004; Sherman et al., 2003) and female sex (Heinonen et al.,
2001; Hjermstad et al., 1999; Prieto et al., 1996) have been reported to be associated with worse
sleep quality among HSCT recipients. There is also evidence to suggest that sleep disruption
may differ for patients undergoing an autologous (receive own cells) or allogeneic (receive donor
cells) transplant (Diez-Campelo et al., 2004; Hjermstad et al., 2004), indicating it may be useful
to examine aspects of sleep disturbance among these two populations separately. However, less
is known about potentially modifiable risk factors for sleep disturbance among HSCT recipients.
Intrusive thoughts and worry have been linked to sleep disruption in non-cancer populations
(Espie, 2007). This may be particularly relevant among cancer patients who are often subjected
to additional cancer-specific concerns such as worry about cancer recurrence and intrusive
thoughts about their cancer. There is some evidence linking cancer-specific factors such as
cancer-related distress and fear of cancer recurrence to sleep disruption (Dupont, Bower,
Stanton, & Ganz, 2014; Taylor et al., 2012). For example, intrusive thoughts were linked to more
disturbed sleep among women with breast cancer four weeks post-treatment; however, intrusive
thoughts did not predict sleep trajectory up to one year later (Dupont et al., 2014). In another
study, cancer-related intrusive thoughts were identified as a risk factor for sleep disturbance
among a small sample of African American breast cancer survivors (Taylor et al., 2012). The
same study found that fear of cancer recurrence did not significantly contribute to disturbed sleep
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above and beyond intrusive thoughts and concluded that automatic thoughts such as cancerrelated distress may play a more important role in predicting sleep disturbance than specific
concerns about recurrence (Taylor et al., 2012). Given the lack of knowledge about modifiable
risk factors among HSCT recipients and the potential importance of cancer-specific variables,
the present study investigated the extent to which cancer-related distress and fear of cancer
recurrence are related to sleep disruption following HSCT.
Cognitive and Behavioral Factors Related to Sleep Disruption
A strong body of evidence exists regarding the contribution of cognitive and behavioral
factors to sleep disruption. This evidence has shown that dysfunctional sleep-related thoughts
and behaviors contribute to the perpetuation of insomnia symptoms (Edinger & Means, 2005;
Morin, Kowatch, Barry & Walton, 1993). Several recent studies have examined the extent to
which cognitive and behavioral factors associated with sleep disruption in other populations
apply in the context of cancer. For example, dysfunctional beliefs and attitudes about sleep, sleep
monitoring, and maladaptive sleep behaviors have been linked to an increased risk for insomnia
incidence in a mixed cancer sample (Savard, Villa, Ivers, Simard, & Morin, 2009). Moreover,
self-reported insomnia symptoms were found to be significantly reduced among breast cancer
survivors receiving individual cognitive-behavioral therapy for insomnia (which included
behavioral components such as sleep restriction and cognitive restructuring of patients’
dysfunctional beliefs and attitudes about sleep) compared to women in a delayed treatment
control group (Fiorentino et al., 2009). Relationships between cognitive-behavioral factors and
sleep disruption have not been investigated among HSCT recipients. Given the known
persistence of sleep disruption among HSCT recipients and the extant sleep literature suggesting
cognitive-behavioral factors are capable of perpetuating sleep disruption, these relationships
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could be especially important to study among this population of patients. Therefore, in addition
to cancer-specific factors, this study determined the extent to which cognitive and behavioral
factors contribute to sleep disruption following HSCT. Specifically, the study investigated the
contribution of dysfunctional beliefs and attitudes about sleep, sleep effort, and inhibitory sleep
habits to sleep disruption following HSCT.
Aims & Hypotheses
Aim 1. To characterize the prevalence and severity of sleep disruption measured both
subjectively and objectively among cancer patients following autologous HSCT.
Aim 2. To characterize the relationship between self-reported and objective indices of
sleep disruption following HSCT. Based on prior literature (Ancoli-Israel et al., 2006; Dhruva et
al., 2012; Grutsch et al., 2011), a modest relationship (observed as a medium effect size) between
subjectively- and objectively-reported sleep disruption was predicted.
Aim 3. To investigate whether cancer-specific factors (i.e., cancer-related distress and
fear of recurrence) are related to sleep disruption following HSCT. Patients with greater cancerrelated distress and fear of cancer recurrence were expected to report greater sleep disruption
measured either subjectively or objectively following HSCT.
Aim 4. To investigate whether cognitive and behavioral factors are related to sleep
disruption following HSCT. Based on prior research on the importance of cognitive-behavioral
factors for insomnia (Edinger & Means, 2005), patients who report greater dysfunctional beliefs
and attitudes about sleep, sleep effort, and inhibitory sleep habits were expected to report greater
sleep disruption measured either subjectively or objectively following HSCT.
Aim 5. To explore the incremental variance accounted for by cancer-specific factors and
cognitive and behavioral factors to sleep disruption following HSCT.
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Method
Participants
The study sample was comprised of adults who underwent an autologous HSCT at the H.
Lee Moffitt Cancer Center for treatment of a hematologic disease. Participants were recruited
between May 2015 and February 2016. Eligibility criteria required that participants: 1) be
diagnosed with a hematologic malignancy, 2) have undergone an autologous HSCT
approximately 6 months to 18 months prior to study enrollment, 3) be ≥18 years of age, 4) have
no history of other cancers other than non-melanoma skin cancer, 5) have no evidence of disease
progression at the time of study enrollment, 6) be able to speak and read English, and 7) be able
to provide informed consent.
Procedures
Study eligibility was determined via consultation with physicians, clinical staff, and
medical record review. Eligible patients returning to clinic for a follow-up appointment within
the next six months were approached during their clinic visit and had the study protocol
explained to them. Those wishing to participate were asked to sign an informed consent form.
They were then given an initial and a follow-up questionnaire, an actigraph, a sleep log, and a
postage-paid envelope. Participants were asked to complete the initial questionnaire assessing
demographics, cognitive and behavioral factors related to sleep disruption, and cancer-specific
factors the day of their clinic visit. Eligible patients who expressed interest in the study but who
were not able to start the study the day of their clinic visit received study materials via mail.
Participants were instructed to wear the actigraph for seven consecutive 24-hour periods and
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complete a sleep log daily to document napping periods, sleep medication use, bedtime, and
wake time. The sleep log was used as an aid in computing objective sleep disruption parameters.
Participants completed a follow-up questionnaire assessing sleep disruption on the seventh and
final day of the study so that both outcome variables (subjective and objective sleep disruption)
covered the same time frame. Participants were instructed to return all study materials in the
postage-paid envelope. Relevant clinical information, including cancer/hematologic diagnosis,
conditioning regimen, number of inpatient hospital days, medications, and disease status, was
collected via medical record review.
Measures (see Appendix)
Demographic characteristics. Participants completed a standardized self-report form
assessing demographics including age, sex, race, ethnicity, education, income, marital status,
employment status, as well as height and weight as part of the initial assessment. Participants
also completed a self-report version of the ECOG performance status scale and reported on
recent use of medications to promote sleep.
Cancer-related distress. Participants completed the intrusion subscale of the Impact of
Events Scale (IES) on the first day of the study. The intrusion subscale of the IES is a 7-item
self-report measure assessing psychological stress during the past week in response to a
particular event. Each item is rated on a 4-point Likert scale where 0 indicates no bother and 3
indicates the patient is often bothered by a particular difficulty. The intrusion subscale of the IES
has demonstrated good validity and internal consistency (Horowitz, Wilner, & Alvarez, 1979),
with a reliability coefficient of α = 0.89 in the current study.
Fear of cancer recurrence. Participants completed the Fear of Cancer Recurrence
Inventory (FCRI) on the first day of the study. The FCRI is a 42-item self-report measure
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assessing fear or worry that cancer will return or progress. This study focused on severity of fear
surrounding the possibility of cancer recurrence as well as functional impairments related to fear
of cancer recurrence. The FCRI has demonstrated excellent construct validity, temporal stability,
and strong internal consistency (Simard & Savard, 2009), with a reliability coefficient of α =
0.94 for the severity subscale and α = 0.93 for the functional impairment subscale in the present
study.
Dysfunctional beliefs and attitudes about sleep. Participants completed the abbreviated
version of the Dysfunctional Beliefs and Attitudes about Sleep (DBAS-16) questionnaire on the
first day of the study. The DBAS-16 is a 16-item, self-report scale assessing faulty beliefs,
worries, and attentional biases surrounding sleep-related cognitions (Morin, Vallieres, & Ivers,
2007). Each item is rated on an 11-point Likert scale where 0 indicates the patient strongly
disagrees with the statement and 10 indicates the patient strongly agrees. A total score is
calculated by averaging the items with a higher score indicating more dysfunctional beliefs and
attitudes about sleep. The DBAS-16 has demonstrated adequate internal consistency α = 0.79,
temporal stability, and concurrent validity among patients with insomnia (Morin et al., 2007) and
has been used with cancer patients (Savard et al., 2009). Internal consistency was very good in
the present study with a reliability coefficient of α = 0.92.
Sleep effort. Participants completed the Glasgow Sleep Effort Scale (GSES) on the first
day of the study. The GSES is a 7-item scale assessing the extent to which individuals engage in
effortful attempts to sleep such as a need for control over sleep and trying too hard to sleep
(Broomfield & Espie, 2005). Each item is rated on a 3-point Likert scale ranging from “very
much true” to “not at all true.” The GSES had demonstrated adequate psychometric properties
with good internal consistency, α = 0.77 among non-cancer patients with insomnia (Broomfield
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& Espie, 2005). The GSES demonstrated good internal consistency in the present study with a
reliability coefficient of α = 0.81.
Sleep hygiene. Participants completed the Sleep Hygiene Index (SHI) on the first day of
the study. The SHI is a 13-item self-report scale assessing the extent to which individuals
practice healthy behaviors that facilitate sleep and avoid behaviors that interfere with sleep
(Mastin, Bryson, & Corwyn, 2006). The SHI is assessed on a 0 to 4-point Likert scale with 0
indicating the patient never engages in a particular behavior and 4 indicating the patient always
engages in a particular behavior. The SHI has demonstrated improved internal consistency (α =
0.66) over prior instruments assessing sleep hygiene and good test-retest reliability (Mastin et al.,
2006). Internal consistency of the SHI was adequate in the present study with a reliability
coefficient of α = 0.70. Participants also completed the Sleep Habits Scale (SHS) on the first day
of the study. The SHS is a 22-item measure assessing the extent to which patients engage in
habits that facilitate or interfere with sleep during the previous week (M. Rumble, personal
communication, March 10, 2014). Items are rated on a 0 to 4-point Likert scale with 0 indicating
a sleep habit (e.g., I take time to relax before I go to bed; I watch the clock when I am awake in
bed) occurred 0 times per week and 4 indicating a sleep habit occurred 6 or more times per week
in the past week. This scale was recently developed by researchers at the University of
Wisconsin-Madison, and its psychometric properties have not been previously assessed; the SHS
demonstrated very good internal consistency in the present study with a reliability coefficient of
α = 0.90.
Self-reported sleep disruption. Participants completed the 7-item Insomnia Severity Index
(ISI) on the seventh and final day of the study. The ISI is a self-report measure assessing the
nature, severity, and impact of insomnia during the past two weeks (Bastien, Vallieres, & Morin,
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2001). For the purposes of the present study, the recall period was revised to the past week. Each
item is rated on a 0 to 4-point Likert scale where 0 indicates no problems and 4 indicates severe
problems. The total ISI score ranges from 0 to 28 and is calculated by summing the seven items.
Total ISI scores are interpreted as follows: 0-7 indicates no clinically significant insomnia, 8-14
indicates subthreshold insomnia, 15-21 indicates clinical insomnia (moderate severity), and 2228 indicates clinical insomnia (severe). The ISI has demonstrated good internal consistency
(Bastien et al., 2001), with a reliability coefficient of α = 0.91 in the present study.
Objective sleep disruption. The Philips Respironics Actiwatch-Score (Philips Healthcare,
Andover, MA) was used to objectively quantify sleep patterns. Participants wore the actigraph
on their non-dominant wrist continuously for a seven-day period. The Actiwatch is 43 x 23 x 10
mm in size, weighs 16 g, and contains a highly sensitive piezoelectric accelerometer (sampling
rate of 32 Hz) that records and averages wrist movements over every minute. Data from the
Actiwatch were downloaded and analyzed using ActiLife v6.10.1 (ActiGraph, LLC, Pensacola,
Florida). Sleep indices were calculated in combination with patient sleep logs using Philips
Actiware 6 software to determine: sleep efficiency or the percentage of time spent sleeping in
relation to time spent in bed, sleep onset latency (SOL) or the amount of time taken to fall asleep,
wake after sleep onset (WASO) or minutes awake after an extended period of sleep, and total
sleep time (TST) or the time spent asleep at night (Berger et al., 2008). Of these, sleep efficiency
served as the primary objective outcome of interest. Sleep efficiency was operationalized as
scored total sleep time divided by the rest interval duration minus total invalid time and
multiplied by 100. SOL was operationalized as the time elapsed between the start of a given rest
interval and the following sleep start time, in minutes. WASO was operationalized as the total
number of epochs between the start time and the end time of the given sleep interval scored as
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wake by Actiware software multiplied by the epoch length in minutes. Finally, TST was
operationalized as the time elapsed between the start time and the end time of the given interval
scored as sleep by Actiware software multiplied by the epoch length in minutes.
Statistical Analyses
Data analyses were performed using SAS Version 13.2 (Cary, NC). Data were first
examined for normality of distribution and outliers. Mean imputation was used to correct for
scales with sporadic missing items. Multiple imputation was used for scales for which all items
were missing. The number of imputed data points for any scale for which all items were missing
never exceeded three participants per scale. To address Aim 1, participants’ scores on the ISI
were summarized with descriptive statistics (e.g., means, standard deviations, and frequencies) to
characterize the prevalence and severity of sleep disruption. Descriptive statistics were also
generated using actigraphy data for the major sleep indices that could be derived. To address
Aim 2, Pearson correlation coefficients were calculated to test the hypothesized relationship
between subjective sleep disruption, as measured by the ISI total score, and objectively measured
sleep disruption, as measured by the sleep efficiency score. The resulting correlation/effect size
was evaluated in relation to the anticipated effect size (r = 0.30).
Following this, medical and sociodemographic variables were examined for their relation
to subjective and objective sleep disruption outcomes. Variables found to be significantly (p <
.10) related to outcome measures were included as covariates in all subsequent analyses. To
address Aim 3, separate hierarchical multiple regression analyses for the subjective and objective
outcome measures described above were conducted to test hypotheses regarding whether the
following cancer-specific factors are related to sleep disruption after accounting for relevant
demographic and clinical variables: (a) cancer-related distress as measured by the IES; and (b)
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fear of cancer recurrence as measured by the FCRI. To address Aim 4, hierarchical multiple
regression analyses were also conducted to test hypotheses regarding whether each of the
following cognitive and behavioral factors was related to sleep disruption after accounting for
relevant demographic and clinical variables: (a) dysfunctional beliefs and attitudes about sleep as
measured by the DBAS; (b) sleep effort as measured by the GSES; and (c) sleep habits as
measured by the SHI. Scales with missing data were corrected by conducting regression analyses
within a multiple imputation framework.
Finally, to address Aim 5, hierarchical multiple regression analyses were conducted to
explore the incremental variance accounted for by cancer distress factors and cognitive and
behavioral factors in predicting sleep disruption following transplantation. Specifically, a series
of successive models were built in order to look at the incremental variance accounted for by
cancer-specific distress and the incremental variance accounted for by cognitive and behavioral
factors over and above clinical demographic factors. In the first model, all significant
demographic and clinical factors from univariate analyses were entered in the first step. In the
second model, significant demographic and clinical factors were entered in the first step and
cancer-specific factors were entered in the second step. This model indicated whether cancerspecific factors accounted for additional variance over and above the influence of relevant
covariates. In the third model, significant demographic and clinical factors were entered in the
first step followed by cognitive and behavioral factors in the second step. This model indicated
whether cognitive and behavioral factors accounted for additional variance over and above the
influence of relevant covariates. In the fourth and final model, significant demographic and
clinical factors were entered in the first step, cancer-specific factors were entered in the second
step, and cognitive and behavioral factors were entered in the third step. This model yielded the

13

total variance accounted for by cancer-specific factors and cognitive and behavioral factors when
all factors were entered in the model.
Based on previous research (Savard et al., 2009; Rumble et al., 2010), effect sizes for
relationships of interest in the present study were expected to be medium (i.e., r = 0.30). A power
analysis using G*Power 3.1 indicated that a sample of 84 patients would be needed to detect
significance of a medium effect (r = 0.30) with a Type I error rate of 0.05 (two-tailed) and power
of 0.80. A second power analysis indicated that a sample of 98 would be needed to detect
significance of a medium effect (f2 = 0.15) with a Type I error rate of 0.05 and a power of 0.80 in
hierarchical multiple regression analyses testing six predictors such as might be included in the
exploratory analyses for Aim 5.
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Results
Recruitment and Patient Characteristics
Based on a priori power analyses, we aimed to recruit 98 HSCT recipients. Figure 1
depicts the flow of patients through the study. Overall, 273 patients were screened for study
eligibility, 189 were deemed eligible, and 124 received a phone call asking if they would be
interested in hearing more about the study when they returned to clinic for a follow-up
appointment. Of these, 8 indicated they were not interested. Therefore, 116 patients were
approached in clinic. Of these, 16 refused participation (primarily due to having too much going
on or simply not being interested) and 100 agreed to participate and signed the study consent
form (overall participation rate = 81%).
Of the 100 patients who agreed to participate, one dropped out before receiving the
baseline study materials, four were ineligible after consent due to disease progression, and three
completed baseline study materials but were then lost to follow-up. A total of 92 patients
completed both the baseline and follow-up assessments. Of those 92 patients, one reported
performing shift-work and was not included in the final sample. Seven patients had less than 3
days of actigraph data primarily due to actigraph recording failure or the patient declining to
wear the actigraph. Descriptive statistics and a t-test revealed that the ISI total score did not
differ between the 7 patients without actigraph data (M = 5.86, SD = 4.38) and the 84 patients
with actigraph data (M = 7.07, SD = 5.58), t(8) = 0.69, p = .51. Therefore, the 7 patients without
actigraph data were excluded and the final sample consisted of 84 HSCT patients.
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See Table 1 for patient demographic and medical characteristics. Patients were an
average of 60 years of age. The majority were male (55%), non-Hispanic (94%), white (87%),
and were highly educated with 68% of patients reporting at least some college. The majority of
patients were diagnosed with multiple myeloma (69%), while 19% were diagnosed with nonHodgkin lymphoma, 10% with Hodgkin lymphoma, and 2% with amyloidosis. At the time of
study participation, patients were an average of 350 days post-transplant and the majority
reported they were not currently taking a sleeping medication (61%).
Sleep Disruption among HSCT Recipients
Table 2 depicts descriptive statistics including means and standard deviations for
subjective and objective sleep disruption. On average, subjective reports of sleep disturbance
based on the ISI were relatively low (M = 7.07, SD = 5.58). Prevalence rates were as follows:
59% of HSCT patients were classified as good sleepers (ISI total scores ≤ 7), 30% had
subthreshold insomnia symptoms (ISI total scores of 8 to 14), 10% met criteria for moderate
clinical insomnia (ISI total scores of 15 to 21), and 1% met criteria for severe clinical insomnia
(ISI total scores ≥ 22). Analysis of the objective indices of sleep disruption revealed that, on
average, patients took 20 minutes to fall asleep at night, spent one hour awake during the night
after initially falling asleep, and spent 6.5 hours asleep at night. Overall, patients had a sleep
efficiency of 78%.
Table 3 depicts descriptive statistics for cancer-specific factors and cognitive and
behavioral factors. On average, patients reported relatively low levels of intrusion (M = 10.53,
SD = 8.21) and functional impairment from fear of cancer progression (M = 5.82, SD = 6.28).
Patients self-reported their fear of cancer progression as moderate in severity (M = 15.67, SD =
8.04). Patients endorsed some dysfunctional beliefs and attitudes about sleep (M = 3.87, SD =
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2.07) as well as sleep effort (M = 3.52, SD = 2.86). Finally, patients reported relatively low levels
of unhealthy sleep habits (SHI M = 26.44, SD = 5.39; SHS M = 26.89, SD = 9.15).
Table 4 depicts relationships among subjective and objective measures of sleep
disruption. HSCT recipients’ subjective reports of sleep disruption were significantly associated
with objectively calculated total sleep time, p = .04. However, subjectively reported sleep was
not significantly associated with any of the other objective measures of sleep disruption, all p’s >
.05. Among objective measures of sleep disruption, sleep efficiency was related to sleep onset
latency, wake after sleep onset, and total sleep time, p’s < .001. Sleep onset latency was related
to wake after sleep onset, p = .01, but not total sleep time, p = .12. Finally, wake after sleep onset
was related to total sleep time, p = .04.
Univariate Analyses with Sleep Disruption
Examination of relationships between sociodemographic and medical characteristics
revealed that age, ethnicity, and time since transplant were the only variables significantly
associated with any of the sleep disruption outcomes, p’s < .10 (see Table 5). Specifically, age
and ethnicity were related to sleep efficiency and sleep onset latency. Given that there were only
four Hispanic patients in the sample, we opted not to control for ethnicity. Also, given that time
since transplant was only related to total sleep time and was unrelated to any other outcome, we
opted not to control for time since transplant. Therefore, age was the only factor controlled for in
subsequent analyses. Table 6 depicts relationships between cancer-specific factors, cognitive and
behavioral factors, and sleep disruption. Regression analyses controlling for age revealed that
IES intrusion, FCRI severity, and FCRI functional impairment were all related with subjective
reports of sleep disruption (ISI total score), all p’s < .04. None of these cancer-specific factors
were significantly related with any of the objective indices of sleep disruption, all p’s > .07.
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Additional univariate analyses revealed that dysfunctional beliefs and attitudes about sleep as
measured by the DBAS, sleep effort as measured by the GSES, and sleep hygiene as measured
by both the SHI and the SHS were related to subjective reports of sleep disruption (ISI total
score), all p’s < .03. None of these cognitive and behavioral factors were significantly related
with any of the objective indices of sleep disruption, all p’s > .05.
Multivariable Analyses with Sleep Disruption
Factors that were significantly (p < .10 for demographic and clinical factors and p < .05
for all other factors) related to subjective sleep disruption in univariate analyses were entered in
the multivariable models predicting subjective sleep disruption as measured by the ISI. Variance
inflation factors were examined and found to be in the appropriate range indicating
multicollinearity was not a problem. Therefore, all factors remained in the models. Table 7
depicts results from the four multivariable models. In the first model, age was entered and
accounted for 1% of the variance. In the second model, IES intrusion, FCRI severity, and FCRI
functional impairment scores were entered after age and accounted for an additional 7% of the
variance compared to the first model, F(4, 78) = 1.48, p > .05. In the third model, DBAS, GSES,
SHI, and SHS scores were entered after age and accounted for an additional 27% of the variance
compared to the first model, F(5, 77) = 5.78, p < .001. In the fourth and final model, age was
again entered in the first step, IES intrusion, FCRI severity, and FCRI functional impairment
were entered in the second step, and DBAS, GSES, SHI, and SHS scores were entered in the
third step. All factors entered together in the same model accounted for 34% of the variance in
subjective sleep and account for additional variance compared to the first model, F(8, 74) = 4.63,
p < .001. No significant relationships were found between cancer-specific factors, cognitive and
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behavioral factors, and objective sleep outcomes in univariate analyses, therefore multivariable
analyses were not conducted with any of the indices of objective sleep disturbance.
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Discussion
The present study sought to characterize subjective and objective sleep disruption and
examine relationships between cancer distress, fear of cancer recurrence, cognitive, and
behavioral factors and sleep disruption among autologous HSCT recipients between 6 and 18
months post-transplant. A majority of patients were characterized as good sleepers based on selfreport, however, 41% of patients met criteria for subclinical or clinical insomnia. While
estimates of the prevalence of sleep disruption in HSCT patients vary widely, results from the
present study are generally in line with estimates in the survivorship period following HSCT
(Nelson et al., 2014; Faulhaber et al., 2010; Diez-Campelo et al., 2004; Watson et al., 2004). In
the only other study to administer the Insomnia Severity Index to transplant patients, Boonstra
and colleagues (2011) found that only 26% of transplant patients could be classified as healthy
sleepers in the acute period post-transplant. Comparisons to data from the present study suggest
that a large percentage of patients’ insomnia naturally remits in the time between hospital stay
and extended survivorship. Examination of actigraphy data revealed that patients spent an
average of 6.5 hours in bed at night, took approximately 20 minutes to fall asleep, and spent over
an hour awake during the night after falling asleep. Moreover, average sleep efficiency was only
78%, which is below the recommended 85% often used as a cut point to indicate healthy sleep
(Schutte-Rodin, Broch, Buysse, Dorsey, & Sateia, 2008). Descriptive reports from the actigraphy
data are novel and add to a previous body of literature, which has heretofore focused on
subjective reports of sleep. Taken together, these descriptive data indicate that a large minority of
HSCT patients could benefit from interventions targeting sleep problems.
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It was hypothesized that subjective reports of sleep disruption would be moderately
correlated with objective sleep disruption. With the exception of total time patients spent asleep
at night, this hypothesis was not supported. At least two possible explanations for this exist.
First, it is possible that subjective and objective sleep indices are not related in general and there
is mixed support for this (Buysse et al., 2008; Lauderdale et al., 2008). A second possibility is
that patients with health conditions may be biased in their reporting of sleep issues. Among
patients with chronic or life-threatening illness, response shift, which refers to a patient’s change
in internal standards, change in values, or reconceptualization of a given construct, is common
(Sprangers & Schwartz, 1999). This shift in perspective may at least in part account for the lack
of a relationship observed between subjective and objective sleep disturbance among patients
with health conditions. If this is the case, this underscores the importance of including objective
measures of sleep in clinical assessment with the understanding that patients who report good
sleep but demonstrate poor objective sleep quality may also benefit from a sleep intervention.
Although self-report has often been shown not to be strongly correlated with actigraphy,
actigraphy has been shown to correlate with polysomnography, the gold-standard for
measurement of sleep and wake states, at a rate of about 90% agreement (Coke, Kripke, Gruen,
Mullaney, & Gillin, 1992). Therefore, actigraphy represents an attractive, more feasible option
for obtaining objective descriptions of sleep among HSCT patients given the cancer, treatment,
and symptom burden already placed on these patients. While speculating on the lack of a
relationship between subjective and objective sleep disruption is interesting, the design of the
current study precludes us from providing definitive conclusions on this issue.
The hypothesis that cognitive and behavioral factors would be associated with subjective
and objective sleep disturbance was partially supported. Significant relationships were found
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between cognitive and behavioral factors and self-reported sleep disruption, but not with
objective measures of sleep disruption. These findings regarding self-reported sleep disruption
are in line with a large and growing body of evidence examining cognition distortions and
maladaptive sleep behaviors as perpetuating factors of insomnia (Savard et al., 2009; Edinger
2005). Findings further suggest that HSCT patients’ cognition distortions and maladaptive sleep
behaviors could be modified to improve sleep. Similarly, the hypothesis that cancer distress and
fear of cancer recurrence would be associated with subjective and objective sleep disturbance
was also partially supported with the same pattern of findings; cancer-specific factors were
associated with subjective but not objective sleep disruption. These findings regarding subjective
sleep disruption are in line with prior literature examining these relationships in other forms of
cancer and suggest that cancer-related distress and fear of cancer recurrence represent additional
modifiable targets in addressing sleep concerns (Savard et al., 2009).
Finally, cognitive factors, including dysfunctional beliefs and attitudes about sleep and
sleep effort, contributed greater incremental variance in predicting subjective sleep compared to
cancer-related distress when all factors were entered into an exploratory multivariable model.
This pattern of results indicates that it may be patients’ distorted cognitions, more than cancerrelated distress or unhealthy sleep behaviors, that are the primary drivers of their self-reported
sleep disruption. If this is the case, it may be particularly important to change distorted
cognitions in addressing HSCT patients’ sleep complaints.
The present study was limited by its cross-sectional assessment of sleep, which prevented
any examination of how relationships between cancer distress, fear of cancer recurrence,
distorted cognitions, maladaptive behaviors, and sleep disruption change over time. The study
was also limited by the lack of ethnic and racial diversity of its participants, which limits
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generalizability to other groups. In addition, while the study was adequately powered for most of
the statistical analyses, it was underpowered for the multivariable analysis, which could have
affected study results from that analysis. The final limitation noted has to do with the way sleep
efficiency (percentage of time asleep in relation to time in bed) was calculated. While the present
study included sleep onset latency, time spent asleep at night, and wake after sleep onset in the
denominator of the calculation of sleep efficiency, it has been suggested that the denominator in
this calculation should also include time attempting to sleep after final awakening (Reed &
Sacco, 2016). Future studies should revise sleep logs to be able to collect this information.
Despite these limitations, the present study adds to a strong foundation of prior literature
examining perpetuating factors of insomnia. Moreover, this study investigated not only
subjective but also objective sleep disruption among a homogenous group of autologous
transplant recipients, which to the best of our knowledge has not been done in HSCT recipient
survivorship.
Results from this study suggest a number of future directions. First, future studies
investigating sleep disruption among HSCT recipients should consider using a longitudinal
design in order to gain a clearer picture of how cancer-related distress, fear of cancer recurrence,
distorted cognitions, and maladaptive sleep behaviors relate to sleep disruption over time. This is
particularly important given the natural waxing and waning pattern of insomnia symptoms over
time and given that transplant does not occur in a vacuum and patients may be dealing with a
number of other physical and psychosocial issues that often fluctuate over time. Second, further
investigation into the relationship between subjectively reported sleep and objectively measured
sleep is warranted. It may be particularly important to determine whether clinicians are missing
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out on treating patients with objective sleep issues due to response shift and patients
underreporting sleep problems.
Third, future research investigating the efficacy of Cognitive Behavioral Therapy for
Insomnia (CBT-I) is of central importance. While a majority of autologous HSCT recipients in
the present study had no clinically significant sleep issues, a large minority of these patients
continued to have insomnia symptoms or insomnia syndrome in the survivorship period. Results
from the present study suggest that many of these patients have dysfunctional cognitions about
sleep and unhelpful behaviors around bedtime, which are ripe targets for a sleep intervention.
Specifically, maladaptive cognitions and behaviors have previously been identified as factors
that perpetuate or maintain sleep disruption over time (Spielman & Glovinsky, 1991). CBT-I
uses stimulus control, sleep restriction, cognitive restructuring, and sleep hygiene to target
factors that perpetuate sleep issues. Moreover, CBT-I is a recommended treatment for clinical
sleep issues in cancer patients (Savard & Savard, 2013; Schutte-Rodin et al., 2008; Edinger &
Means, 2005). The relationships between sleep and maladaptive cognitions and behaviors among
HSCT recipients described in the present study suggest that HSCT recipients may benefit from a
CBT-I intervention. A number of barriers to pursuing CBT-I in the context of cancer have been
identified including a shortage of trained professionals, time and costs of treatment delivery, and
patient transportation burden and costs (Savard & Savard, 2013). These concerns have produced
a growing body of research examining different modes of treatment delivery including individual
therapy, group therapy, and interactive web-based treatment (Savard, Ivers, Savard, & Morin,
2014; Zhou, Partridge, & Recklitis, 2016). HSCT recipients have a uniquely high treatment and
symptom burden; however, with these new modes of delivery comes hope that this potentially
efficacious treatment for sleep issues could be more widely disseminated. Given the large body
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of evidence demonstrating that sleep concerns are a prevalent and problematic issue often
persisting into the survivorship period following HSCT, there is a critical need for research
investigating interventions for sleep disturbance among these patients. Therefore, research
investigating the efficacy of CBT-I among HSCT recipients should be prioritized.
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Table 1. Demographic and Medical Characteristics
Characteristic
Age, years
M
SD

59.67
11.91

Gender, No. (%)
Male
Female

46 (54.8)
38 (45.2)

Ethnicity, No. (%)
Not Hispanic
Hispanic
Missing

79 (94.0)
4 (4.8)
1 (1.2)

Race, No. (%)
White
Nonwhite

73 (86.9)
11 (13.1)

Marital Status, No. (%)
Married
Not married

64 (76.2)
20 (23.8)

Education, No. (%)
High school or less
College or more
Missing

26 (31.0)
57 (67.8)
1 (1.2)

Employment, No. (%)
Work full-time or part-time
Retired
Other
Missing

26 (31.0)
32 (38.1)
25 (29.7)
1 (1.2)

Income, No. (%)
< 40K
≥ 40K
Missing

31 (36.9)
36 (42.9)
17 (20.2)

Cancer type, No. (%)
Multiple Myeloma
Hodgkin lymphoma
Non-Hodgkin lymphoma
Amyloidosis

58 (69.0)
8 (9.5)
16 (19.1)
2 (2.4)
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Table 1 (Continued)
Characteristic
Functional Status, No. (%)
4
3
2
1
Missing

40 (47.6)
35 (41.7)
6 (7.1)
1 (1.2)
2 (2.4)

Sleeping Medication, No. (%)
Yes
No
Missing

32 (38.1)
51 (60.7)
1 (1.2)

Note. SD = standard deviation.
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Table 2. Subjective and Objective Sleep Disruption Descriptive Statistics
Outcomes

Score range
possible
0 – 28

M (SD)

Min

Max

7.07 (5.58)

0

22

SE, %

0 – 100

78.03 (9.44)

42.33

91.64

SOL, min

0 – 1440

21.20 (16.66)

1.29

77.86

WASO, min

0 – 1440

66.03 (34.29)

23.00

196.71

TST, min

0 – 1440

390.49 (72.60)

128.14

543.14

ISI total score

Note. ISI = Insomnia Severity Index, SE = Sleep Efficiency, SOL = Sleep Onset Latency,
WASO = Wake After Sleep Onset, TST = Total Sleep Time.
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Table 3. Cancer-Specific Factors and Cognitive and Behavioral Factors Descriptive Statistics
Predictors

Score range
possible
0 – 35

Reliability
Coefficient
0.89

M (SD)

Min

Max

IES Intrusion

Number of
items
7

10.53 (8.21)

0.00

31.00

FCRI Severity

9

0 – 36

0.94

15.67 (8.04)

0.00

31.50

FCRI
Impairment
DBAS

6

0 – 24

0.93

5.82 (6.28)

0.00

23.00

16

0 – 10

0.92

3.87 (2.07)

0.25

9.25

GSES

7

0 – 14

0.81

3.52 (2.86)

0.00

11.00

SHI

13

13 – 65

0.70

26.44 (5.39)

14.00

41.00

SHS

22

0 – 88

0.90

26.89 (9.15)

6.47

45.29

Note. IES = Impact of Events Scale, FCRI = Fear of Cancer Recurrence Inventory, DBAS =
Dysfunctional Beliefs and Attitudes about Sleep, GSES = Glasgow Sleep Effort Scale, SHI =
Sleep Habits Index, SHS = Sleep Habits Scale.
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Table 4. Relationships Among Subjective and Objective Sleep Disruption (N = 84)
ISI total score
ISI total score

SE

SOL

WASO

1.0

SE

-0.19

1.0

SOL

0.08

-0.55***

1.0

WASO

0.13

-0.77***

0.27*

1.0

-0.23*

0.65***

-0.17

-0.23*

TST

TST

1.0

Note. Pearson correlation coefficients depicted in table. ISI = Insomnia Severity Index, SE =
Sleep Efficiency, SOL = Sleep Onset Latency, WASO = Wake After Sleep Onset, TST = Total
Sleep Time. * p < .05, ** p < .01, *** p < .001.
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Table 5. Relationship Between Demographic and Medical Factors and Sleep Disruption
ISI total score

SE

SOL

WASO

TST

r

p

r

p

r

p

r

p

r

p

Age

-0.13

.25

0.19

.08

-0.25

.02

-0.05

.65

0.14

.20

Gender

0.11

.32

0.07

.55

0.03

.80

-0.11

.30

0.07

.56

Ethnicity

0.16

.17

0.24

.04

-0.30

.008

-0.06

.64

0.10

.37

Race

0.00

1.00

0.09

.44

-0.10

.38

0.04

.74

0.16

.16

Marital Status

-0.03

.77

-0.02

.89

0.13

.24

-0.06

.58

0.05

.66

Education

0.01

.90

0.08

.49

-0.01

.89

0.03

.76

0.03

.79

Employment

-0.15

.17

0.01

.96

0.00

.99

-0.02

.84

-0.08

.47

Income

0.05

.68

0.11

.39

0.00

1.00

-0.16

.21

0.10

.41

Cancer Type

0.09

.42

0.16

.15

-0.18

.10

-0.09

.41

0.03

.79

Time Since
Transplant

-0.17

.12

0.09

.43

-0.09

.41

0.03

.81

0.24

.03

Note. Relationships between continuous variables are based on Pearson correlation coefficients
while relationships between dichotomous and continuous variables are based on point-biserial
correlation coefficients. Significant relationships (p < .10) are bolded. ISI = Insomnia Severity
Index, SE = Sleep Efficiency, SOL = Sleep Onset Latency, WASO = Wake After Sleep Onset,
TST = Total Sleep Time.
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Table 6. Relationships Between Cancer-Specific Factors, Cognitive and Behavioral Factors, and
Subjective and Objective Sleep Disturbance After Controlling for Age

ISI total score
Psychological
Factors

R

IES Intrusion

2

SE

β

p

R

0.07

0.27

.02

FCRI Severity

0.07

0.24

FCRI
Impairment

0.10

DBAS

2

SOL

β

p

R

0.08

0.18

.10

.03

0.04

0.11

0.31

.005

0.05

0.29

0.54

<.001

GSES

0.46

0.68

SHI

0.07

SHS

0.24

2

WASO

β

p

R

0.07

-0.04

.73

.32

0.07

.11

-0.15

.18

0.10

0.03

0.01

.91

<.001

0.03

-0.09

0.27

.02

0.03

0.49

<.001

0.04

2

TST

β

p

R

0.01

-0.08

.47

.32

0.01

-0.04

0.19

.08

0.01

0.08

0.15

.17

.42

0.07

0.15

0.02

.89

0.12

0.09

.42

0.06

2

β

p

0.06

0.18

.11

.71

0.05

0.18

.10

.10

.39

0.02

-0.04

.75

0.00

0.01

.94

0.03

0.10

.36

.15

0.01

0.05

.65

0.02

-0.04

.71

-0.24

.98

0.02

-0.11

.33

0.03

-0.14

.23

0.08

.48

0.01

-0.04

.71

0.03

0.08

.47

Note. Significant p values are bolded. ISI = Insomnia Severity Index, SE = Sleep Efficiency,
SOL = Sleep Onset Latency, WASO = Wake After Sleep Onset, TST = Total Sleep Time, IES =
Impact of Events Scale, FCRI = Fear of Cancer Recurrence Inventory, DBAS = Dysfunctional
Beliefs and Attitudes about Sleep, GSES = Glasgow Sleep Effort Scale, SHI = Sleep Habits
Index, SHS = Sleep Habits Scale.
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Table 7. Multivariable Hierarchical Regression Models with Subjective Sleep Disruption
R2

ΔR2

β

p

0.01

-

-

-

-

-

-0.10

.37

0.08

0.07

-

> .05

Age

-

-

0.02

.88

IES Intrusion

-

-

0.15

.27

FCRI Severity

-

-

0.03

.82

FCRI Impairment

-

-

0.23

.07

0.28

0.27

-

< .001

Age

-

-

0.04

.61

DBAS

-

-

0.15

.18

GSES

-

-

0.49

<.001

SHI

-

-

0.03

.75

SHS

-

-

0.14

.20

0.34

0.33

-

< .001

Age

-

-

0.06

.48

IES Intrusion

-

-

0.01

.89

FCRI Severity

-

-

-0.16

.18

FCRI Impairment

-

-

0.14

.16

DBAS

-

-

0.15

.19

GSES

-

-

0.49

<.001

SHI

-

-

0.03

.75

SHS

-

-

0.17

.12

Variable
Model 1
Age
Model 2

Model 3

Model 4
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Note: ISI = Insomnia Severity Index, SE = Sleep Efficiency, SOL = Sleep Onset Latency,
WASO = Wake After Sleep Onset, TST = Total Sleep Time, IES = Impact of Events Scale,
FCRI = Fear of Cancer Recurrence Inventory, DBAS = Dysfunctional Beliefs and Attitudes
about Sleep, GSES = Glasgow Sleep Effort Scale, SHI = Sleep Habits Index, SHS = Sleep
Habits Scale.
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Enrollment

Screened (n=273)
Excluded (n=84)
• Recurrence/Progression (n=25)
• History of other malignancies (n=22)
• Non-English speaking (n=12)
• HSCT other than autologous (n=9)
• <6 or >18 months post-HSCT (n=9)
• Tandem Autologous HSCT (n=5)
• Deceased (n=2)

Eligible (n=189)
Could not be reached / No appointment (n=27)
Eligible/Pending at time of study close (n=38)
Approached (n=124)
• Refused over phone (n=8)
• Refused in clinic (n=16)

Consented (n=100)

Study Period

Ineligible after consent (disease progression; n=4)
Discontinued participation (n=1)

Baseline (n=95)
Lost to follow-up (n=3)

Follow-up (n=92)
Excluded from analysis (n=8)
• No actigraphy data (actigraph recording
failure, patient did not want to wear
actigraph, n=7)
• Shift-worker (n=1)

Analysis

Included in Analysis (n=84)
Figure 1. Flow Diagram
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